CN117462668A - 用抗pd-1抗体治疗肿瘤的方法 - Google Patents

用抗pd-1抗体治疗肿瘤的方法 Download PDF

Info

Publication number
CN117462668A
CN117462668A CN202311104154.0A CN202311104154A CN117462668A CN 117462668 A CN117462668 A CN 117462668A CN 202311104154 A CN202311104154 A CN 202311104154A CN 117462668 A CN117462668 A CN 117462668A
Authority
CN
China
Prior art keywords
antibody
tumor
subject
mutation
stk11
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311104154.0A
Other languages
English (en)
Chinese (zh)
Inventor
R·爱德华兹
W·J·格泽
D·M·格里纳沃尔特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN117462668A publication Critical patent/CN117462668A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202311104154.0A 2017-06-01 2018-06-01 用抗pd-1抗体治疗肿瘤的方法 Pending CN117462668A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762513831P 2017-06-01 2017-06-01
US62/513,831 2017-06-01
CN201880035434.1A CN110678483B (zh) 2017-06-01 2018-06-01 用抗pd-1抗体治疗肿瘤的方法
PCT/US2018/035670 WO2018223040A1 (en) 2017-06-01 2018-06-01 Methods of treating a tumor using an anti-pd-1 antibody

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880035434.1A Division CN110678483B (zh) 2017-06-01 2018-06-01 用抗pd-1抗体治疗肿瘤的方法

Publications (1)

Publication Number Publication Date
CN117462668A true CN117462668A (zh) 2024-01-30

Family

ID=62685228

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880035434.1A Active CN110678483B (zh) 2017-06-01 2018-06-01 用抗pd-1抗体治疗肿瘤的方法
CN202311104154.0A Pending CN117462668A (zh) 2017-06-01 2018-06-01 用抗pd-1抗体治疗肿瘤的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201880035434.1A Active CN110678483B (zh) 2017-06-01 2018-06-01 用抗pd-1抗体治疗肿瘤的方法

Country Status (6)

Country Link
US (3) US11566073B2 (enExample)
EP (1) EP3630840A1 (enExample)
JP (2) JP7780857B2 (enExample)
KR (2) KR102714702B1 (enExample)
CN (2) CN110678483B (enExample)
WO (1) WO2018223040A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102702287B1 (ko) * 2012-05-15 2024-09-04 브리스톨-마이어스 스큅 컴퍼니 Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
AU2016305697B2 (en) 2015-08-11 2023-02-02 WuXi Biologics Ireland Limited Novel anti-PD-1 antibodies
US11566073B2 (en) 2017-06-01 2023-01-31 Bristol-Myers Squibb Company Methods of treating a tumor using an anti-PD-1 antibody
BR112020016331A8 (pt) * 2018-02-13 2023-02-07 Merck Sharp & Dohme Métodos para tratar câncer com anticorpos anti-pd-1
CN111821434A (zh) * 2019-04-17 2020-10-27 上海君实生物医药科技股份有限公司 抗pd-1抗体在制备治疗实体瘤的药物中的用途
US20220081724A1 (en) * 2018-12-19 2022-03-17 Strata Oncology, Inc. Methods of detecting and treating subjects with checkpoint inhibitor-responsive cancer
WO2020226986A2 (en) * 2019-05-03 2020-11-12 Genentech, Inc. Methods of treating cancer with an anti-pd-l1 antibody
US12275986B2 (en) * 2020-01-06 2025-04-15 Duke University Biomarkers associated with checkpoint immune therapy and methods of using same
CN110923329B (zh) * 2020-02-06 2020-05-12 至本医疗科技(上海)有限公司 Fgfr4点突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用
CN111440822A (zh) * 2020-04-16 2020-07-24 苏州大学附属第二医院 一种突变lats1质粒的构建与应用
CN112961920A (zh) * 2021-03-24 2021-06-15 臻和(北京)生物科技有限公司 一种预测肝胆肿瘤患者免疫检查点抑制剂联合靶向治疗疗效的方法及产品
JP2023025595A (ja) * 2021-08-10 2023-02-22 国立大学法人 新潟大学 内胚葉嚢胞の悪性化に関連する遺伝子の検出方法
CN113943806A (zh) * 2021-11-04 2022-01-18 至本医疗科技(上海)有限公司 预测肺腺癌患者对免疫疗法敏感性的生物标志物、应用和装置
EP4515000A1 (en) * 2022-04-26 2025-03-05 F. Hoffmann-La Roche AG Methods and systems for predicting cancer therapy response
CN114931637B (zh) * 2022-06-27 2025-02-18 中山大学中山眼科中心 Pdl1抗体在角膜新生血管疾病中的应用
CN115825441B (zh) * 2023-01-30 2023-05-26 上海秤信生物科技有限公司 预测肺癌三期患者的免疫新辅助疗效的自身抗体标志物
WO2025085707A1 (en) * 2023-10-19 2025-04-24 Tesaro, Inc. Methods of treating cancer with anti-pd-1 agents

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1210428T3 (en) 1999-08-23 2015-06-15 Dana Farber Cancer Inst Inc PD-1, a receptor for B7-4 AND USE THEREOF
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP2535354B1 (en) 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
CN104961829B (zh) 2009-11-24 2018-08-21 米迪缪尼有限公司 针对b7-h1的靶向结合剂
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-pd-l1 항체 및 그의 용도
KR102702287B1 (ko) 2012-05-15 2024-09-04 브리스톨-마이어스 스큅 컴퍼니 Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
KR102410078B1 (ko) 2012-05-31 2022-06-22 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
PT2992017T (pt) 2013-05-02 2021-01-29 Anaptysbio Inc Anticorpos dirigidos contra a morte programada 1 (pd-1)
HK1221964A1 (zh) 2013-05-31 2017-06-16 Sorrento Therapeutics, Inc. 与pd-1结合的抗原结合蛋白
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
RS63571B9 (sr) 2013-09-13 2023-02-28 Beigene Switzerland Gmbh Anti-pd1 antitela i njihova primena kao terapeutska i dijagnostička sredstva
PL3081576T3 (pl) 2013-12-12 2020-03-31 Shanghai Hengrui Pharmaceutical Co., Ltd. Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne
DE112014005975T5 (de) * 2013-12-17 2016-09-15 Kymab Limited Menschliche Ziele
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
AU2015210886A1 (en) * 2014-01-29 2016-09-01 Caris Mpi, Inc. Molecular profiling of immune modulators
CA2944903A1 (en) * 2014-04-24 2015-10-29 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
EP3237446B1 (en) 2014-12-22 2021-05-05 PD-1 Acquisition Group, LLC Anti-pd-1 antibodies
WO2016149201A2 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
US20180155429A1 (en) * 2015-05-28 2018-06-07 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
US10696745B2 (en) 2015-06-11 2020-06-30 Wuxi Biologics (Shanghai) Co. Ltd. Anti-PD-L1 antibodies
SG10202010506TA (en) 2015-07-30 2020-11-27 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AU2016305697B2 (en) 2015-08-11 2023-02-02 WuXi Biologics Ireland Limited Novel anti-PD-1 antibodies
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
CN107949573B (zh) 2015-09-01 2022-05-03 艾吉纳斯公司 抗-pd-1抗体及其使用方法
US20170114098A1 (en) * 2015-09-03 2017-04-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10954301B2 (en) 2015-12-14 2021-03-23 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
EP3402512A4 (en) 2016-01-11 2019-09-25 Armo Biosciences, Inc. INTERLEUKIN-10 IN THE PREPARATION OF ANTIGEN-SPECIFIC CD8 + T CELLS AND METHOD FOR THE USE THEREOF
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
CN108029076B (zh) 2016-02-02 2020-03-10 华为技术有限公司 确定发射功率的方法、用户设备和基站
EP3464369A1 (en) 2016-06-03 2019-04-10 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treating a tumor
US11566073B2 (en) 2017-06-01 2023-01-31 Bristol-Myers Squibb Company Methods of treating a tumor using an anti-PD-1 antibody
CN113249483B (zh) * 2021-06-10 2021-10-08 北京泛生子基因科技有限公司 一种检测肿瘤突变负荷的基因组合、系统及应用

Also Published As

Publication number Publication date
KR20200014363A (ko) 2020-02-10
US20200109204A1 (en) 2020-04-09
KR102714702B1 (ko) 2024-10-10
EP3630840A1 (en) 2020-04-08
JP2023159179A (ja) 2023-10-31
US20230279114A1 (en) 2023-09-07
KR20240149982A (ko) 2024-10-15
JP2020522508A (ja) 2020-07-30
US11566073B2 (en) 2023-01-31
JP7780857B2 (ja) 2025-12-05
US12227576B2 (en) 2025-02-18
CN110678483B (zh) 2023-09-22
CN110678483A (zh) 2020-01-10
WO2018223040A1 (en) 2018-12-06
US20250145713A1 (en) 2025-05-08

Similar Documents

Publication Publication Date Title
CN110678483B (zh) 用抗pd-1抗体治疗肿瘤的方法
US12466888B2 (en) Methods of treating tumor
KR102775647B1 (ko) 종양을 치료하는 방법
US20240190963A1 (en) Methods of treating tumor
US12479917B2 (en) Methods of treating NSCLC comprising administering platinum doublet chemotherapy followed by an anti-PD-1 antibody and an anti-CTLA-4 antibody
WO2023196987A1 (en) Methods of treating tumor
EA046134B1 (ru) Способы лечения опухоли

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination